{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:32:38Z","timestamp":1793424758288,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s10067-026-08448-6","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:17:50Z","timestamp":1790648270000},"page":"6583-6593","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Renal function\u2013adjusted initial JAK inhibitor dosing and outcomes in rheumatoid arthritis: from the ANSWER cohort study"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9762-5055","authenticated-orcid":false,"given":"Daisuke","family":"Tomita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2810-1519","authenticated-orcid":false,"given":"Yuji","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Yamazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Ishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chisato","family":"Ashida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsu","family":"Itami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Shiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0810-4221","authenticated-orcid":false,"given":"Wataru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7896-3937","authenticated-orcid":false,"given":"Koichi","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9372-726X","authenticated-orcid":false,"given":"Hideo","family":"Onizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9241-060X","authenticated-orcid":false,"given":"Motomu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0033-1757","authenticated-orcid":false,"given":"Masao","family":"Katsushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2426-1024","authenticated-orcid":false,"given":"Kosuke","family":"Ebina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4668-1718","authenticated-orcid":false,"given":"Iku","family":"Shirasugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6065-8486","authenticated-orcid":false,"given":"Yo","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7244-7715","authenticated-orcid":false,"given":"Yonsu","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7015-377X","authenticated-orcid":false,"given":"Naofumi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0065-929X","authenticated-orcid":false,"given":"Tohru","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0023-3616","authenticated-orcid":false,"given":"Shogo","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1809-5143","authenticated-orcid":false,"given":"Koji","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"8448_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, McInnes IB et al (2018) Rheumatoid arthritis. Nat Rev Dis Primers 4:18001. https:\/\/doi.org\/10.1038\/nrdp.2018.1","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"8448_CR2","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1080\/14397595.2019.1682776","volume":"30","author":"M Kojima","year":"2020","unstructured":"Kojima M, Nakayama T, Tsutani K et al (2020) Epidemiological characteristics of rheumatoid arthritis in Japan: prevalence estimates using a nationwide population-based questionnaire survey. Mod Rheumatol 30(6):941\u2013947. https:\/\/doi.org\/10.1080\/14397595.2019.1682776","journal-title":"Mod Rheumatol"},{"issue":"7","key":"8448_CR3","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/1756-185X.12998","volume":"20","author":"E Kato","year":"2017","unstructured":"Kato E, Sawada T, Tahara K et al (2017) The age at onset of rheumatoid arthritis is increasing in Japan: a nationwide database study. Int J Rheum Dis 20(7):839\u2013845. https:\/\/doi.org\/10.1111\/1756-185X.12998","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"8448_CR4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3109\/14397595.2015.1088620","volume":"26","author":"K Saisho","year":"2016","unstructured":"Saisho K, Yoshikawa N, Sugata K, Hamada H, Tohma S (2016) Prevalence of chronic kidney disease and administration of RA-related drugs in patients with rheumatoid arthritis: the NinJa 2012 study in Japan. Mod Rheumatol 26(3):331\u2013335. https:\/\/doi.org\/10.3109\/14397595.2015.1088620","journal-title":"Mod Rheumatol"},{"issue":"5","key":"8448_CR5","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s10165-012-0773-z","volume":"23","author":"A Nakajima","year":"2013","unstructured":"Nakajima A, Saito K, Kojima T et al (2013) No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan. Mod Rheumatol 23(5):945\u2013952. https:\/\/doi.org\/10.1007\/s10165-012-0773-z","journal-title":"Mod Rheumatol"},{"issue":"11","key":"8448_CR6","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s40266-022-00976-5","volume":"39","author":"M Novella Navarro","year":"2022","unstructured":"Novella Navarro M, Balsa A (2022) Difficult-to-treat rheumatoid arthritis in older adults: implications of ageing for managing patients. Drugs Aging 39(11):841\u2013849. https:\/\/doi.org\/10.1007\/s40266-022-00976-5","journal-title":"Drugs Aging"},{"issue":"5","key":"8448_CR7","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/acr.22713","volume":"68","author":"M Couderc","year":"2016","unstructured":"Couderc M, Tatar Z, Pereira B et al (2016) Prevalence of renal impairment in patients with rheumatoid arthritis: results from a cross-sectional multicenter study. Arthritis Care Res (Hoboken) 68(5):638\u2013644. https:\/\/doi.org\/10.1002\/acr.22713","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"8448_CR8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","volume":"16","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O\u2019Shea JJ (2017) JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 16(12):843\u2013862. https:\/\/doi.org\/10.1038\/nrd.2017.201","journal-title":"Nat Rev Drug Discov"},{"key":"8448_CR9","unstructured":"U.S. Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. 1 September 2021. Available at: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death. Accessed 16 March 2026"},{"key":"8448_CR10","unstructured":"European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 24\u201327 October 2022. 27 October 2022. Available at: https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-24-27-october-2022. Accessed 16 March 2026"},{"issue":"4","key":"8448_CR11","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR et al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386(4):316\u2013326. https:\/\/doi.org\/10.1056\/NEJMoa2109927","journal-title":"N Engl J Med"},{"issue":"1","key":"8448_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/jcph.288","volume":"54","author":"S Krishnaswami","year":"2014","unstructured":"Krishnaswami S, Chow V, Boy M et al (2014) Pharmacokinetics of tofacitinib in patients with varying degrees of renal impairment. J Clin Pharmacol 54(1):46\u201352. https:\/\/doi.org\/10.1002\/jcph.288","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"8448_CR13","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1111\/bcp.13726","volume":"84","author":"F Namour","year":"2018","unstructured":"Namour F, Fagard L, van der Aa A, Harrison P, Xin Y, Tasset C (2018) Influence of age and renal impairment on the steady-state pharmacokinetics of filgotinib, a selective JAK1 inhibitor. Br J Clin Pharmacol 84(12):2779\u20132789. https:\/\/doi.org\/10.1111\/bcp.13726","journal-title":"Br J Clin Pharmacol"},{"key":"8448_CR14","unstructured":"Eli Lilly Japan K.K. Olumiant\u00ae Tablets 4 mg, 2 mg, and 1 mg (baricitinib) [electronic package insert]. Eli Lilly Japan K.K, Kobe. https:\/\/www.pmda.go.jp\/PmdaSearch\/rdDetail\/iyaku\/3999043F1020_1. Accessed 27 Sep 2026"},{"issue":"6","key":"8448_CR15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109078","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J et al (2012) Efficacy of tofacitinib monotherapy in rheumatoid arthritis (ORAL Solo): a randomised phase 3 trial. N Engl J Med 367(6):495\u2013507. https:\/\/doi.org\/10.1056\/NEJMoa1109078","journal-title":"N Engl J Med"},{"issue":"6","key":"8448_CR16","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1107722","volume":"367","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven RF, Fleischmann R, Cohen S et al (2012) Efficacy and safety of tofacitinib or adalimumab versus placebo in rheumatoid arthritis (ORAL Standard): a randomised controlled phase III trial. N Engl J Med 367(6):508\u2013519. https:\/\/doi.org\/10.1056\/NEJMoa1107722","journal-title":"N Engl J Med"},{"issue":"1","key":"8448_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","volume":"76","author":"M Dougados","year":"2017","unstructured":"Dougados M, van der Heijde D, Chen Y-C et al (2017) Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs (RA-BUILD study). Ann Rheum Dis 76(1):88\u201395. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210094","journal-title":"Ann Rheum Dis"},{"issue":"13","key":"8448_CR18","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Kremer JM, Zamani O et al (2016) Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 374(13):1243\u20131252. https:\/\/doi.org\/10.1056\/NEJMoa1507247","journal-title":"N Engl J Med"},{"issue":"4","key":"8448_CR19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jama.2019.9055","volume":"322","author":"MC Genovese","year":"2019","unstructured":"Genovese MC, Kalunian K, Gottenberg JE et al (2019) Filgotinib vs placebo or adalimumab in rheumatoid arthritis refractory to biological DMARDs: the FINCH 2 randomized clinical trial. JAMA 322(4):315\u2013325. https:\/\/doi.org\/10.1001\/jama.2019.9055","journal-title":"JAMA"},{"issue":"7","key":"8448_CR20","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","volume":"80","author":"B Combe","year":"2021","unstructured":"Combe B, Kivitz A, Tanaka Y et al (2021) Filgotinib in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial (FINCH 3). Ann Rheum Dis 80(7):848\u2013858. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219214","journal-title":"Ann Rheum Dis"},{"key":"8448_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-04075-0","volume":"12","author":"K Ebina","year":"2022","unstructured":"Ebina K, Hirano T, Maeda Y et al (2022) Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. Sci Rep 12:134. https:\/\/doi.org\/10.1038\/s41598-021-04075-0","journal-title":"Sci Rep"},{"key":"8448_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-024-01360-w","volume":"24","author":"Y Nakayama","year":"2024","unstructured":"Nakayama Y, Onishi A, Yamamoto W et al (2024) Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study. Clin Exp Med 24:97. https:\/\/doi.org\/10.1007\/s10238-024-01360-w","journal-title":"Clin Exp Med"},{"issue":"2","key":"8448_CR23","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1093\/rheumatology\/keae081","volume":"64","author":"S Jinno","year":"2025","unstructured":"Jinno S, Onishi A, Hattori S et al (2025) Comparison of retention of biologics in Japanese patients with elderly-onset rheumatoid arthritis\u2014the ANSWER cohort study. Rheumatology (Oxford) 64(2):509\u2013516. https:\/\/doi.org\/10.1093\/rheumatology\/keae081","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"8448_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA et al (1988) The 1987 revised American Rheumatism Association criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315\u2013324. https:\/\/doi.org\/10.1002\/art.1780310302","journal-title":"Arthritis Rheum"},{"issue":"9","key":"8448_CR25","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69(9):1580\u20131588. https:\/\/doi.org\/10.1136\/ard.2010.138461","journal-title":"Ann Rheum Dis"},{"key":"8448_CR26","unstructured":"Pfizer Japan Inc. Xeljanz\u00ae Tablets 5 mg (tofacitinib citrate) [electronic package insert]. Pfizer Japan Inc, Tokyo. https:\/\/www.pmda.go.jp\/PmdaSearch\/rdDetail\/iyaku\/3999034F1020_2. Accessed 27 Sep 2026"},{"key":"8448_CR27","unstructured":"European Medicines Agency. Jyseleca\u00ae (filgotinib) EPAR\u2014Product information. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/jyseleca. Accessed 18 July 2025"},{"key":"8448_CR28","doi-asserted-by":"publisher","first-page":"b2393","DOI":"10.1136\/bmj.b2393","volume":"338","author":"JAC Sterne","year":"2009","unstructured":"Sterne JAC, White IR, Carlin JB et al (2009) Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 338:b2393. https:\/\/doi.org\/10.1136\/bmj.b2393","journal-title":"BMJ"},{"issue":"4","key":"8448_CR29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/sim.4067","volume":"30","author":"IR White","year":"2011","unstructured":"White IR, Royston P, Wood AM (2011) Multiple imputation using chained equations: issues and guidance for practice. Stat Med 30(4):377\u2013399. https:\/\/doi.org\/10.1002\/sim.4067","journal-title":"Stat Med"},{"issue":"1","key":"8448_CR30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/rheumatology\/kez320","volume":"59","author":"T St\u00fcrmer","year":"2020","unstructured":"St\u00fcrmer T, Wang T, Golightly YM, Robinson W, Campbell SE (2020) Methodological considerations when analysing and interpreting real-world data. Rheumatology (Oxford) 59(1):14\u201325. https:\/\/doi.org\/10.1093\/rheumatology\/kez320","journal-title":"Rheumatology (Oxford)"},{"key":"8448_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/9780470316696","volume-title":"Multiple imputation for nonresponse in surveys","author":"DB Rubin","year":"1987","unstructured":"Rubin DB (1987) Multiple imputation for nonresponse in surveys. John Wiley & Sons, New York"},{"issue":"3","key":"8448_CR32","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 46(3):399\u2013424. https:\/\/doi.org\/10.1080\/00273171.2011.568786","journal-title":"Multivariate Behav Res"},{"issue":"3","key":"8448_CR33","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48(3):452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"8448_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s41927-024-00446-y","volume":"8","author":"A Maeyama","year":"2024","unstructured":"Maeyama A, Kondo M, Harada H et al (2024) Efficacy and safety of baricitinib in rheumatoid arthritis patients with moderate renal impairment: a multicenter propensity score-matching study. BMC Rheumatol 8(1):69. https:\/\/doi.org\/10.1186\/s41927-024-00446-y","journal-title":"BMC Rheumatol"},{"key":"8448_CR35","doi-asserted-by":"publisher","first-page":"e1506","DOI":"10.1007\/s00393-024-01506-x","volume":"83","author":"O Schultz","year":"2024","unstructured":"Schultz O, Fiehn C, Kneitz C et al (2024) Real-world experience with filgotinib for rheumatoid arthritis in Germany: a retrospective chart review. Z Rheumatol 83:e1506\u2013e1516. https:\/\/doi.org\/10.1007\/s00393-024-01506-x","journal-title":"Z Rheumatol"},{"issue":"11","key":"8448_CR36","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1093\/rheumatology\/kead543","volume":"63","author":"S Hayashi","year":"2024","unstructured":"Hayashi S, Tachibana S, Maeda T et al (2024) Real-world comparative study of the efficacy of JAK inhibitors in rheumatoid arthritis: the ANSWER cohort study. Rheumatology (Oxford) 63(11):3033\u20133041. https:\/\/doi.org\/10.1093\/rheumatology\/kead543","journal-title":"Rheumatology (Oxford)"},{"key":"8448_CR37","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1093\/rheumatology\/keaf050","volume":"64","author":"Y Yoshimura","year":"2025","unstructured":"Yoshimura Y, Yamanouchi M, Koizumi R et al (2025) Efficacy and safety of first-line targeted synthetic DMARDs in rheumatoid arthritis patients with chronic kidney disease. Rheumatology (Oxford) 64:3396\u20133404. https:\/\/doi.org\/10.1093\/rheumatology\/keaf050","journal-title":"Rheumatology (Oxford)"},{"key":"8448_CR38","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.3390\/jcm12094585","volume":"12","author":"J Temmoku","year":"2023","unstructured":"Temmoku J, Koga T, Sato M et al (2023) Drug retention rates and the safety of Janus kinase inhibitors in elderly patients with rheumatoid arthritis. J Clin Med 12:4585. https:\/\/doi.org\/10.3390\/jcm12094585","journal-title":"J Clin Med"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08448-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08448-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08448-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:05:33Z","timestamp":1793423133000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08448-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["8448"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08448-6","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"14 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"D.T. has no conflicts of interest to declare. Y.N. has received speaker fees from AbbVie, Astellas Pharma, Asahi Kasei Pharma, Chugai Pharmaceutical, Eisai, Eli Lilly, GlaxoSmithKline, and Mitsubishi Tanabe Pharma. R.F., Y.M., H.Y., K.I., C.A., T.I., T.S. have no conflicts of interest to declare. W.Y. has no conflicts of interest to declare. K.Murata has received speaking and\/or consulting fees from Asahi Kasei Pharma, Chugai Pharmaceutical, UCB Japan, Eli Lilly, AbbVie, and Daiichi Sankyo. H.O. has no conflicts of interest to declare. M.H. has received research grants and\/or speaker fees from Asahi Kasei Pharma, Astellas Pharma, AstraZeneca, Ayumi Pharmaceutical, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Eli Lilly, Gilead Sciences Japan, Janssen Pharmaceutical, Ono Pharmaceutical, Taisho Pharmaceutical, Mitsubishi Tanabe Pharma, and UCB Japan. M.K. has no conflicts of interest to declare. K.E. has received research grants from Asahi Kasei Pharma and Teijin Pharma. K.E. has received payments for lectures from AbbVie, Amgen, Asahi Kasei Pharma, Astellas Pharma, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly, Gilead Sciences, Ono Pharmaceutical, Pfizer, Taisho Pharmaceutical, Mitsubishi Tanabe Pharma, and Teijin Pharma. K.E. holds an additional post at the Department of Sports Medical Biomechanics, The University of Osaka Graduate School of Medicine Faculty of Medicine, supported by Asahi Kasei Pharma. I.S. has no conflicts of interest to declare. Y.U. has received research grants and\/or speaker fees from Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, GlaxoSmithKline, Kissei Pharmaceutical, and Taisho Pharmaceutical. Y.S., N.Y. have no conflicts of interest to declare. T.T. has received research grants and\/or speaker fees from Asahi Kasei Pharma, Astellas Pharma, AstraZeneca, Boehringer Ingelheim, Chugai Pharmaceutical, Eisai, Eli Lilly, Otsuka Pharmaceutical, Taisho Pharmaceutical, Mitsubishi Tanabe Pharma, and UCB Japan. S.M. has received research grants from the Japan Intractable Diseases Research Foundation and the Promotion and Mutual Aid Corporation for Private Schools of Japan. K.K. has no conflicts of interest to declare.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}